Compare Bristol-Myers Squibb Co (BMY) vs iShares MSCI Germany (DAX) (EWG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares MSCI Germany (DAX) — how do they compare? Bristol-Myers Squibb Co trades at $63.86 (market cap $129.94B), while iShares MSCI Germany (DAX) trades at $43.84. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals.
| BMY | EWG | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $65.89 | $44.56 |
52-Week Low | $42.60 | $38.08 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
EWG trades at $43.815, down slightly by 0.13% on the day, with a bullish technical signal driven by moving averages but neutral oscillators. The stock lacks available fundamental data for valuation and profitability metrics. Recent news highlights European Central Bank policy and German economic developments influencing regional market sentiment.
The outlook remains tied to European economic trends and monetary policy. Risks include energy price volatility and geopolitical tensions, while opportunities may arise from German fiscal support and market rotations into European equities. Investors should assess fundamental data when available for a complete view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →
